Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?

Conditions: Polyneuropathies, Diabetic Complications Neurological, Diabetes Mellitus Type 2

Sex: All

Ages: 30 Years – 75 Years

Healthy volunteers: Yes

Enrollment: 81

Sponsor: GÜLDEN ANATACA

Summary

Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.

Eligibility Criteria

Inclusion Criteria: * Age between 30 and 75 years * Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups) * Ability to understand and sign informed consent * Willingness to participate in the study Exclusion Criteria: * Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy) * Chronic kidney disease (eGFR \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07734597). StuddyBuddy aggregates publicly available trial information.